AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name:	Proton Pump Inhibitors Post Limit	Page:	1 of 3
Effective Date:	10/12/2023	Last Review Date:	10/2023

Applies to:	☒Illinois	☐Florida	☒Florida Kids
	☒New Jersey	☒Maryland	☐Michigan
	☒Pennsylvania Kids	☒Virginia	☐Kentucky PRMD

Intent:

The intent of this policy/guideline is to provide information to the prescribing practitioner outlining the coverage criteria for Proton Pump Inhibitors Post Limit under the patient's prescription drug benefit.

Indication	**AcipHex** (rabeprazole)	**AcipHex Sprinkles** (rabeprazole)	**Dexilant** (dexlansoprazole)	**Konvomep** (omeprazole/ sodium bicarbonate)	**Nexium** (esomeprazole) **Esomeprazole strontium**	**Prevacid** (lansoprazole)	**Prilosec** (omeprazole)	**Protonix** (pantoprazole)	**Zegerid** (omeprazole/ sodium bicarbonate)
Short-term treatment active duodenal ulcer	✓					✓	✓		✓
H. pylori eradication reduce risk ulcer relapse	✓				✓	✓	✓		
Maintenance healing duodenal ulcers						✓			
Short-term treatment gastric ulcer				✓		✓	✓		✓
Short-term treatment symptoms GERD	✓	✓	✓		✓	✓	✓	✓	✓
Short-term treatment erosive esophagitis / GERD	✓		✓		✓	✓	✓	✓	✓
Maintenance healing erosive esophagitis	✓		✓		✓	✓	✓	✓	✓
Pathological hypersecretory conditions	✓				✓	✓	✓	✓	
Short-term treatment NSAID-gastric ulcer						✓			
Risk reduction of NSAID-gastric ulcer					✓	✓			

Risk reduction upper GI bleed critically ill				✓					✓ Suspension

Description:

Applicable Drug List:

Rabeprazole
Dexlansoprazole
Esomeprazole Strontium
Esomeprazole
Lansoprazole
Omeprazole
Pantoprazole
Omeprazole-Sodium Bicarbonate

Policy/Guideline:

The requested drug will be covered with prior authorization when the following criteria are met:

- The requested drug is being prescribed for any of the following: A) Barrett's esophagus as confirmed by biopsy, B) Hypersecretory syndrome, such as Zollinger-Ellison, confirmed with a diagnostic test

OR

- The requested drug is being prescribed for any of the following: A) Endoscopically verified peptic ulcer disease, B) Frequent and severe symptoms of chronic gastroesophageal reflux disease (GERD), C) Atypical symptoms or complications of GERD

OR

- The patient is at high risk for gastrointestinal (GI) adverse events
  [Note: Risk factors for serious GI adverse events include, but are not limited to, the following: chronic nonsteroidal anti-inflammatory drug (NSAID) therapy, history of peptic ulcer disease and/or GI bleeding, treatment with oral corticosteroids, treatment with anticoagulants, poor general health status, or advanced age.]

Approval Duration and Quantity Restrictions:

Approval:

12 months

Quantity Level Limit:
Reference Formulary for drug specific quantity level limits

References:

1. Aciphex [package insert]. Wixom, MI: Woodward Pharma Services LLC; March 2022.
2. Aciphex Sprinkles [package insert]. Rockville, MD: Atyu Therapeutics, LLC/Cerecor, Inc.; December 2020.
3. Dexilant [package insert]. Lexington, MA: Takeda Pharmaceuticals America, Inc.; March 2022.
4. Esomeprazole Strontium [package insert]. Ripley, MS: Sterling Knight Pharmaceuticals LLC; April 2022.
5. Konvomep [package insert]. Woburn, MA: Azurity Pharmaceuticals, Inc.; December 2022.
6. Nexium [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; March 2022.
7. Omeprazole Capsules [package insert]. East Windsor, NJ: Aurobindo Pharma USA, Inc.; February 2022.
8. Prevacid, Prevacid SoluTab [package insert]. Lexington, MA: Takeda Pharmaceuticals America, Inc.; March 2022.
9. Prilosec Granules [package insert]. Zug, Switzerland: Covis Pharma; March 2022.
10. Protonix [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals LLC; March 2022.
11. Zegerid [package insert]. Bridgewater, NJ: Salix Pharmaceuticals; March 2022.
12. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2023. https://online.lexi.com. Accessed February 22, 2023.
13. Micromedex (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: https://www.micromedexsolutions.com/ (cited: 02/22/2023).
14. Shaheen N, Falk G, Iyer P, et al. Diagnosis and Management of Barrett's Esophagus: An Updated ACG Guideline. *Am J Gastroenterol*. 2022; 117:559-587.
15. Katz P, Dunbar K, Schnoll-Sussman F, et al. ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease. *Am J Gastroenterol*. 2022; 117:27-56.
16. Falconi M, Eriksson B, Kaltsas G, et al. Consensus guidelines update for the management of functional p-NETs (F-p-NETs) and non-functional p-NETs (NF-p-NETs). Neuroendocrinology. 2016; 103(2): 153–171.
17. Kavitt R, Lipowska A, Anyane-Yeboa A, et al. Diagnosis and Treatment of Peptic Ulcer Disease. The American Journal of Medicine (2019) 132:447–456
18. Lanza FL, Chan F, Quigley E, et al. Guidelines for Prevention of NSAID-Related Ulcer Complications. *Am J Gastroenterol* 2009; 104: 728-738.